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REVIEWS AND COMMENTARY • STATEMENTS AND GUIDELINES
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Inaugural consensus statements were developed and endorsed by the American College of Radiology (ACR) and the National
Kidney Foundation to improve and standardize the care of patients with kidney disease who have indication(s) to receive ACRdesignated group II or group III intravenous gadolinium-based contrast media (GBCM). The risk of nephrogenic systemic fibrosis
(NSF) from group II GBCM in patients with advanced kidney disease is thought to be very low (zero events following 4931 administrations to patients with estimated glomerular filtration rate [eGFR] ,30 mL/min per 1.73 m2; upper bounds of the 95%
confidence intervals: 0.07% overall, 0.2% for stage 5D chronic kidney disease [CKD], 0.5% for stage 5 CKD and no dialysis). No
unconfounded cases of NSF have been reported for the only available group III GBCM (gadoxetate disodium). Depending on the
clinical indication, the potential harms of delaying or withholding group II or group III GBCM for an MRI in a patient with acute
kidney injury or eGFR less than 30 mL/min per 1.73 m2 should be balanced against and may outweigh the risk of NSF. Dialysis
initiation or alteration is likely unnecessary based on group II or group III GBCM administration.
This article is a simultaneous joint publication in Radiology and Kidney Medicine. The articles are identical except for stylistic changes in keeping with each journal’s style. Either version may be used in citing this article.
© 2020 RSNA and the National Kidney Foundation published by Elsevier Inc. This is an open access article under the CC BY NC-ND license.
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t is estimated that approximately 50 million doses
of gadolinium-based contrast media (GBCM; also
known as gadolinium-based contrast agents or GBCAs)
are injected annually, and that since 1988 more than
500 million doses have been administered worldwide,
comprising approximately one-third of MRI examinations (1,2). While GBCM-enhanced MRI examinations
are preferred over unenhanced examinations for many
indications, they may be delayed or denied in patients
with impaired kidney function due to concerns of adverse events, including nephrogenic systemic fibrosis
(NSF) and nephrotoxicity. However, recommendations
about the use of GBCM in patients with kidney disease
have evolved and have been inconsistent in clinical practice among radiologists and nephrologists, even within
the same institution (3).
A multidisciplinary group of five radiologists
(J.C.W., C.L.W., R.J.M., J.R.D., M.S.D.) and four nephrologists (R.A.R., J.Y., D.F., M.A.P.) was convened
by the American College of Radiology (ACR) and the
National Kidney Foundation (NKF), with the intention
of improving and standardizing the care of patients with

impaired kidney function who have indication(s) to receive intravenous GBCM. Participants were selected
based on known expertise and interest in the subject.
Although these statements are based on a combination of the most current scientific evidence and expert
consensus opinion, it is important to recognize that in
clinical practice, decisions to administer GBCM may
not be based on a single consideration (eg, risk of an
adverse event specifically related to kidney impairment)
but instead are influenced by many factors (eg, probability and necessity of an accurate diagnosis, alternative
methods of diagnosis, risks of delayed or misdiagnosis,
comorbidities, expectations regarding kidney function
recovery, and the risk of an allergic-like reaction). Consequently, recommendations in this document should be
considered in the context of the entire clinical scenario.
Conditions purported to be associated with gadolinium retention following GBCM administration are not
addressed in this document because they are described
irrespective of kidney function or particular GBCM.
The clinical significance of retained gadolinium in humans is incompletely characterized (2).
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Abbreviations
ACR = American College of Radiology, AKI = acute kidney injury,
CKD = chronic kidney disease, eGFR = estimated glomerular filtration
rate, GBCM = gadolinium-based contrast media, NKF = National Kidney Foundation, NSF = nephrogenic systemic fibrosis

Summary
Since the risk of nephrogenic systemic fibrosis is so low with group
II gadolinium-based contrast media (GBCM), the potential harms
of delaying or withholding group II GBCM for an MRI in a patient
with acute kidney injury or estimated glomerular filtration rate less
than 30 mL/min per 1.73m2 is likely to outweigh the risk in most
clinical situations.

Nomenclature
Acute Kidney Injury and Chronic Kidney Disease
Recommended definitions pertaining to intravenous contrast
media administration for acute kidney injury (AKI), chronic
kidney disease (CKD), contrast-induced acute kidney injury,
and contrast-associated acute kidney injury are provided in a
previously published ACR-NKF consensus document on intravenous iodinated contrast media (4).

Background
Gadolinium and GBCM
Gadolinium, a rare earth metal in the lanthanide series of the
periodic table, has been used in most MRI intravenous contrast
media because it is strongly paramagnetic, thereby altering the
relaxation of water in such a way that it may permit discrimination between normal and abnormal tissues in humans. However, “free” gadolinium from salts such as trichloride is toxic due
to insolubility, interactions with calcium-dependent biologic
processes, cytotoxic effects, and inhibition of mononuclear
phagocytes (5). To minimize toxicity while maintaining desired
paramagnetic properties in commercially available GBCM, gadolinium is chelated to organic ligands, conferring more favorable
pharmacologic and toxicologic properties. Most GBCM distribute primarily in extracellular fluid, demonstrate little protein
binding, and are predominantly excreted in urine by glomerular filtration. However, some GBCM exhibit more pronounced
protein binding and/or partial hepatobiliary excretion.
GBCM are categorized as linear or macrocyclic based on
the molecular structure of the organic ligand and as nonionic
or ionic based on their net charge in solution (Table 1). In general, macrocyclic GBCM are thermodynamically very stable (ie,
low ratio of free gadolinium to complexed ligand at equilibrium)
and more kinetically inert (ie, longer half-life for dissociation of
gadolinium from its ligand) than are linear GBCM (6).
NSF and GBCM Exposure
NSF is a potentially debilitating and sometimes fatal systemic
fibrotic condition that occurs almost exclusively in patients with
AKI or severe CKD (estimated glomerular filtration rate [eGFR]
,30 mL/min per 1.73 m2). Skin and subcutaneous abnormalities (eg, skin thickening, contractures, pruritus, hyperpigmenta2

tion) and ocular findings (scleral plaques) are common, but NSF
also can cause fibrosis of the viscera (eg, lungs, esophagus, and
heart). The diagnosis of NSF requires a combination of clinical history, clinical criteria using a specified scoring system, and
deep skin biopsy (7).
The development of NSF is almost certainly triggered by exposure to GBCM, but the development of disease after exposure
to GBCM is idiosyncratic, and the mechanism is still poorly understood (8,9). The interval between GBCM exposure and onset
of symptoms attributed to NSF ranges from the same day to
approximately 10 years (median, 42 days) (8).
Unconfounded NSF refers to cases where there is confirmation that only one specific GBCM was administered in single
or multiple doses before the development of NSF. Confounded
NSF refers to cases in which there was more than one specific
GBCM administered prior to development of NSF, or there was
no confirmation that only one specific GBCM was administered.
By 2012, 1603 NSF cases had been reported to the United
States Food and Drug Administration Adverse Events Reporting
System. This number may have included duplicates, confounded
cases, and unconfirmed cases (9). Since 2008, the number of
reported cases of NSF has dramatically declined to single digits, likely secondary to regulatory actions, decreased utilization
of group I GBCM, and changes in clinical practice guidelines
(8,10). It also is possible there is underreporting of NSF to the
Food and Drug Administration (11).

Key Questions and ACR-NKF Statements
Table 2 summarizes the major ACR-NKF consensus statements on use of intravenous GBCM in patients with kidney
disease, and Table 3 provides comparison of these statements
to historical ACR (from 2018) and Kidney Disease Improving
Global Outcomes (from 2013) guidelines.

Who Is at Risk for NSF?
The link between GBCM and NSF was first proposed in 2006
(12,13) and has since been confirmed in numerous studies (8).
Patients at greatest risk for NSF include those undergoing renal
replacement therapy, those with AKI, and those at stages 4 or
5 CKD with exposure to a group I GBCM (Table 1), especially if repeated doses of a group I GBCM are administered at
higher-than-recommended doses (8). In a study of 83 121 patients, the incidence of NSF among 58 patients with AKI who
received high-dose group I GBCM was 19% (14). In a 2011
systematic review (15) of 370 biopsy-confirmed cases of NSF,
the incidence in individual series ranged 0%–18%, with 99%
(228 of 231) of verified administrations being group I GBCM
or a mixed GBCM exposure. All patients with known kidney
function in that series (n = 353 of 370) were undergoing dialysis, had eGFR less than 30 mL/min per 1.73 m2, or had
AKI (15). The authors acknowledged controversy regarding the
three cases linked to a macrocyclic agent (15). There are rare
published reports of NSF in patients with stage 3 CKD (eGFR
of 30–59 mL/min per 1.73 m2) (16–18). Some of these reports
were of questionable validity, and there are no published reports of NSF in patients with eGFR greater than or equal to 60
mL/min per 1.73 m2.
radiology.rsna.org n Radiology: Volume 00: Number 0— 2020
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Table 1: ACR Classification of GBCM Relative to Association with NSF

U.S. Trade Name

Generic Name

Structure

ACR Group

Omniscan
OptiMark
Magnevist
MultiHance
ProHance
Gadavist
Dotarem
Clariscan
Eovist

Gadodiamide
Gadoversetamide
Gadopentetate dimeglumine
Gadobenate dimeglumine
Gadoteridol
Gadobutrol
Gadoterate meglumine
Gadoterate meglumine
Gadoxetate disodium

Linear nonionic
Linear nonionic
Linear ionic
Linear ionic
Macrocyclic nonionic
Macrocyclic nonionic
Macrocyclic ionic
Macrocyclic ionic
Linear ionic

I
I
I
II
II
II
II
II
III

Note.—Group I: gadolinium-based contrast media (GBCM) associated with the greatest number of nephrogenic systemic fibrosis (NSF) cases. Group I GBCM are no longer advertised in the United States. Group II: GBCM associated
with few, if any, unconfounded cases of NSF. Group III: GBCM for which data remains limited regarding NSF risk, but
for which few, if any, unconfounded cases of NSF have been reported. ACR = American College of Radiology.

Table 2: Summary of Major ACR-NKF Consensus Statements on Use of Intravenous Gadolinium-containing Contrast
Media in Patients with Kidney Disease

Summary
1. Patients undergoing renal replacement therapy, patients with AKI, and patients with stage 4 or 5 CKD who are exposed to a group I
GBCM—especially repeated doses of a higher off-label dose of a group I GBCM—are at greatest risk of NSF.
2. Risk of NSF differs between GBCM and can be stratified into three GBCM groups (group I: highest risk; group II: very low risk;
group III: likely very low risk but insufficient confirmatory evidence).
3. The risk of NSF increases with larger doses of group I GBCM. The dose-related risk of NSF from group II and group III GBCM is
unknown, but in general the lowest diagnostic dose of GBCM should be used.
4. Group II GBCM should not be withheld or delayed if harm would result from not proceeding with an indicated contrast-enhanced
MRI.
5. Kidney function screening is optional for group II GBCM but is necessary for group III GBCM.
6. Direct communication between the radiologist and referring provider regarding risk of NSF is not necessary for group II GBCM
administration, but it is suggested for group III GBCM administration in patients with eGFR ,30 mL/min per 1.73 m2 or AKI.
7. The risk of NSF is very low for a standard dose (0.1 mmol/kg) of group II GBCM, even in patients with eGFR ,30 mL/min per
1.73 m2 or AKI.
8. Prophylaxis is not indicated for the prevention of NSF. Risk mitigation strategies can include awaiting kidney function recovery and use
of group II GBCM.
9. Dialysis should not be initiated or altered based on group II or group III GBCM administration.
10. On-label dosing of group II or group III GBCM does not have a clinically important risk of nephrotoxicity.
11. If multiple urgent group II or group III GBCM doses are indicated, subsequent dose(s) should not be delayed for fear of NSF. If not
urgent, delaying the subsequent dose(s) .24 hours or performing intercurrent dialysis can promote GBCM clearance.
12. The above recommendations should not be altered in patients receiving nephrotoxic medications, chemotherapy, or contrast-enhanced
CT.
13. The above recommendations also apply to pediatric patients. The risk of NSF in pediatric patients appears to be low, but data are
limited. The Bedside Schwartz equation or the creatinine-cystatin C-based CKiD equation should be used to assess eGFR in infants and
children.
Note.—ACR = American College of Radiology, AKI = acute kidney injury, CKD = chronic kidney disease, eGFR = estimated glomerular
filtration rate, GBCM = gadolinium-based contrast media, NKF = National Kidney Foundation, NSF = nephrogenic systemic fibrosis.

NSF does not appear to be related to the cause or duration of
kidney disease (8). Initial concerns about other risk factors such
as coincident liver disease without associated kidney disease have
not been supported in the literature (19).

Is the Risk of NSF the Same for All GBCM?
The ACR categorizes GBCM into three groups (Table 1) based
on their risk association with NSF (20). This risk classification
is endorsed in these statements.
Radiology: Volume 00: Number 0— 2020 n radiology.rsna.org

Group I: Nearly all unconfounded cases of NSF have been
linked to one of the three linear group I GBCM. These GBCM
are no longer advertised in the United States and have been withdrawn from the market in other countries. Therefore, no specific
recommendations regarding group I GBCM use are included in
this document.
Group II: Few, if any, unconfounded cases of NSF have
been associated with group II GBCM. These include the linear
ionic GBCM gadobenate dimeglumine (MultiHance; Bracco
3
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Table 3: Comparison of Major Current ACR-NKF Consensus Statements to Historical ACR (from 2018) and KDIGO (from 2013)
Guidelines

Consensus Statement

Comparison to Historical ACR and KDIGO Guidelines

1

ACR: Similar statement of risk
KDIGO: Similar statement of risk, but macrocyclic versus linear GBCM are considered rather than ACR GBCM
groups
ACR: Identical GBCM risk grouping
KDIGO: GBCM risk is differentiated by macrocyclic versus linear structure. Gadobenate dimeglumine (linear
ionic group II) and gadoxetate disodium (linear ionic group III) are not distinguished from linear group I GBCM.
ACR: Similar recommendation
KDIGO: Closely spaced repeat doses of GBCM should be avoided.
ACR: Similar recommendation
KDIGO: Similar recommendation
ACR: Similar recommendation
KDIGO: Not specifically addressed, but screening for all GBCM is implied
ACR: Not specifically addressed
KDIGO: Not specifically addressed
ACR: Similar recommendation
KDIGO: Macrocyclic GBCM are recommended if eGFR ,30 mL/min per 1.73 m2 and GBCM should be
avoided if eGFR ,15 mL/min per 1.73 m2 unless there is no alternative.
ACR: Use of prophylaxis is not specifically addressed.
KDIGO: Use of prophylaxis is not specifically addressed.
ACR: For patients already undergoing dialysis, GBCM should be administered as soon as possible before dialysis.
Repeated dialysis sessions are not recommended.
KDIGO: For patients already undergoing dialysis, dialysis should be performed immediately after GBCM
administration and possibly again 24 hours later.
ACR: Not specifically addressed
KDIGO: Not specifically addressed
ACR: Group II GBCM should be used when multiple doses are indicated.
KDIGO: Closely spaced doses should be avoided.
ACR: Not specifically addressed
KDIGO: Not specifically addressed
ACR: Similar recommendation
KDIGO: Measurement of eGFR is challenging in neonates and young infants. Use of GBCM in neonates should
be avoided if possible due to difficulty assessing kidney function and immature kidneys.

2
3
4
5
6
7
8
9

10
11
12
13

Note.—See also Table 2. ACR = American College of Radiology, eGFR = estimated glomerular filtration rate, GBCM = gadolinium-based contrast media, KDIGO = Kidney Disease Improving Global Outcomes, NKF = National Kidney Foundation. Source.—References 10, 46–49.

Diagnostics, Princeton, NJ; ~5% hepatobiliary excretion) and all
macrocyclic GBCM (gadoterate meglumine [Dotarem; Guerbet,
Villepinte, France and Clariscan; GE Healthcare, Oslo, Norway], gadobutrol [Gadavist; Bayer Healthcare, Whippany, NJ],
and gadoteridol [ProHance; Bracco Diagnostics]). Gadobenate
dimeglumine (MultiHance; Bracco Diagnostics) is considered
group II because the evidence supporting a very low risk of NSF
is actually greater for gadobenate than it is for the macrocyclic
GBCM (21–23). The mechanism is unclear, but it may relate to
its partial hepatobiliary excretion. In a review of 405 patients diagnosed with NSF (8), group II GBCM exposures were reported
in 23 patients; however, only two were unconfounded (16,21).
Two additional patients with NSF were administered a group II
GBCM with another unknown GBCM, precluding an assessment of confounding (22). In a 2019 systematic review and metaanalysis (23) of 4931 group II GBCM administrations in patients
with stage 4 or 5 CKD (eGFR ,30 mL/min per 1.73 m2), the
risk of NSF was 0% (zero cases in 4931 subjects; upper bound of
the 95% confidence interval: 0.07%). A subsequent subanalysis
4

of these data stratified by CKD stage found the upper bound of
the 95% confidence interval of risk to be 0.2% (one case for every
500 exposed patients) for stage 5D CKD (eGFR ,15 mL/min
per 1.73 m2 undergoing maintenance dialysis) based on zero cases
in 1849 exposed individuals, and 0.5% (one case for every 200
exposed patients) for stage 5 CKD (eGFR ,15 mL/min per 1.73
m2 not undergoing maintenance dialysis) based on zero cases in
732 exposed individuals (24). For all patients with stage 5 or 5D
CKD, the upper bound of the 95% confidence interval of risk
was 0.1% (one case for every 1000 exposed patients) based on
zero cases in 2581 exposed individuals (24). Thus, while the risk
of NSF following exposure to group II GBCM is low, that risk
estimate is based on data from only 2581 individuals with CKD
stages 5 (n = 732) or 5D (n = 1849) (24).
Group III: Few, if any, unconfounded cases of NSF have been
associated with group III GBCM administration, but data remain limited about NSF risk due to few published administrations in high-risk patients. The only currently available group
III GBCM is gadoxetate disodium (Eovist or Primovist; Bayer
radiology.rsna.org n Radiology: Volume 00: Number 0— 2020
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Healthcare; ~50% hepatobiliary excretion). It is marketed and
primarily used for the detection and characterization of focal
liver lesions. No unconfounded cases of NSF have been reported
for gadoxetate disodium. The largest published study of NSF
risk from gadoxetate disodium included one cohort of 85 patients with stage 4 or 5 CKD or undergoing dialysis, and another
cohort of 193 patients with stage 3 CKD; no NSF events were
observed (25).
The difference in NSF risk among GBCM groups is likely explained by the different kinetic labilities of linear (more labile) and
macrocyclic (less labile) GBCM, and differences in pharmacologic
properties among GBCM (ie, degree of hepatobiliary excretion
and/or degree of protein binding) (26). A combination of other
factors, including market share, number of years a GBCM was in
use, differential dosing, differences in patient populations, reporting bias, and confounded NSF events may have contributed to
differences in apparent risk. To address the possibility of market
share bias as a potential explanation for apparent risk differences,
a hypothetical balanced market share analysis was performed in
conjunction with a systematic review of biopsy-confirmed NSF
(8). That analysis determined that group I GBCM were associated
with an approximately 190-fold increased rate of NSF compared
with group II GBCM (1.52 vs 0.008 per million average-risk population exposures; P , .001) (8).

Is There an Association between NSF and the
Dose of GBCM?
Before the association of GBCM with NSF, contrast media–enhanced MRI and MR angiography examinations with intravenous group I GBCM were commonly substituted for iodinated
contrast-enhanced CT or CT angiography in patients with impaired kidney function. In the United States, it was previously
common to administer “double” or greater doses of group I
GBCM because GBCM were considered nonnephrotoxic.
Also, high doses of GBCM were occasionally administered
intra-arterially for standard angiography and intravenously
for CT scans in lieu of iodinated contrast media in patients
with impaired kidney function. These now-abandoned (except
in some instances of cardiac MRI) clinical practices likely increased the risk of NSF.
In a review of 182 patients with NSF, only 19 (10%) patients
received the standard dose (0.1 mmol/kg) of GBCM, while 163
(90%) received more than the standard dose (27). In a retrospective cohort study, NSF was documented in zero of 74 124
(0%) patients who received the standard dose (approximately
0.1 mmol/kg) of GBCM and 15 of 8997 (0.17%; P , .001)
patients who received a higher dose (20–60 mL, approximately
0.2–0.4 mmol/kg) (14). All confirmed NSF associations occurred after administration of a group I GBCM. In a study of
849 patients undergoing maintenance dialysis (28), multiple presumably group I GBCM exposures increased the risk of developing NSF compared with a single exposure or no exposure (odds
ratio, 44.5 for multiple exposures vs 6.7 for single exposure; and
0.0 for no exposures). These data demonstrate increased risk for
NSF after administration of larger doses of group I GBCM.
Although the risk of NSF following intravenous administration of Food and Drug Administration–approved doses of group
Radiology: Volume 00: Number 0— 2020 n radiology.rsna.org

II and possibly group III GBCM is extremely low, the risk associated with greater doses or intra-arterial administration has not
been assessed. Therefore, the risk-to-benefit ratio determination
for these applications is less certain and subject to radiologist
consideration. In general, the lowest diagnostic dose of GBCM
should be used, regardless of whether it is on-label or off-label.

Should Screening for Kidney Disease Be Used to
Identify Patients at Risk for NSF prior to GBCM
Administration?
In 2010, the Food and Drug Administration issued a black
box warning for all GBCM with the recommendation of kidney function screening before GBCM administration to identify patients with AKI or stage 4 or 5 CKD (29). However, it
is now apparent that the risk of NSF varies by GBCM and
is extremely low for group II GBCM, even in high-risk patients (3,7,8,29). Based on these updated data, the ACR, European Society of Urogenital Radiology, and Canadian Association of Radiology have issued recommendations liberalizing
the administration of group II GBCM in high-risk patients
(20,30,31). In contrast to the Food and Drug Administration,
these organizations do not consider group II GBCM to be contraindicated in high-risk patients and consider kidney function
screening prior to use of group II GBCM optional. However,
unlike the ACR and the Canadian Association of Radiology,
the European Society of Urogenital Radiology advises “caution” when administering group II GBCM to patients with
eGFR less than 30 mL/min per 1.73 m2 (30).
Although there are no validated unconfounded cases of NSF
associated with group III GBCM, the available data are sparse
as utilization has been much less than group I and group II
GBCM. Thus, screening for kidney disease is still recommended
when a group III GBCM is used.
If Kidney Function Screening Is Indicated, How Should
Screening for Kidney Disease Be Performed and which
Patient Risk Factors Should Be Used to Trigger Kidney
Function Assessment?
Screening for kidney disease prior to GBCM administration
is a two-step process. First, if kidney function screening is indicated, clinical risk factors are evaluated that predict whether
AKI or stage 4 or 5 CKD might be present. Second, if one
or more clinical risk factors is present, eGFR measurement is
obtained. If a patient has active AKI or is undergoing dialysis,
kidney function screening is not indicated because eGFR measurement is not reliable in those settings, and these patients
are already at high risk for NSF. Details of kidney function
screening including methods and risk factors are provided in
a previously published ACR-NKF consensus document on intravenous iodinated contrast media (4).
What eGFR Threshold, If Any, Should Be Used by Radiology
Practices to Trigger Direct Contact with the Referring
Provider prior to Administering GBCM, and Should It Be
Modified by Other Risk Factors?
Depending on individual practice patterns, group II GBCM
may be administered to high-risk patients without kidney
5
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function screening and without contact with the referring
provider. If a patient scheduled to receive group III GBCM is
determined to be at high risk for NSF (ie, AKI or eGFR ,30
mL/min per 1.73 m2), this should prompt active consideration
of the risks and benefits associated with GBCM-enhanced imaging, consideration of alternative diagnostic strategies, and
communication between the radiologist and the referring provider. Although written documentation of informed consent
is not required before administration of group II or group III
GBCM, patients with known AKI or known stage 4 or 5 CKD
should be informed of the potential risk of NSF associated
with GBCM administration, the reason GBCM administration is indicated, and whether there are viable alternative diagnostic strategies.
In a Patient with Kidney Disease, Is There Prophylaxis
Available that Can Reduce the Risk of NSF?
No prophylaxis is known to reduce the risk of NSF in high-risk
patients. Risk mitigation strategies include awaiting kidney
function recovery prior to GBCM administration and using
group II GBCM.

Should Dialysis Be Initiated or Accelerated
in Patients with Kidney Disease Who Receive
GBCM?
Although hemodialysis is effective in removing GBCM from
the body (32–34), a reduction in risk of NSF is only theoretical and has not been demonstrated in randomized controlled trials. Hemodialysis is more effective than peritoneal
dialysis in removing GBCM (34). When medically appropriate, GBCM administration optimally should be timed
before a regularly scheduled hemodialysis session in patients
who are already undergoing dialysis. If this is not feasible,
dialysis should be conducted at its regularly scheduled day
and time. No form of dialysis is considered prophylactic for
NSF (34).
Even though dialysis can improve GBCM clearance, due
to the attendant risk of catheter placement and infection, the
possibility of worsening kidney function in those with AKI and
CKD, and the perceived very low risk of NSF from group II
and group III GBCM, dialysis should not be initiated or altered
based on group II or group III GBCM administration. Specifically, daily dialysis or multiple per-day dialysis sessions are not
considered necessary.

Should GBCM Be Considered Nephrotoxic When
Administered Using an On-Label Dose?
Although GBCM are colloquially assumed to be nonnephrotoxic, data indicate they may be nephrotoxic in humans and
animals at sufficiently high doses (35–38). AKI is listed as an
adverse reaction in the prescribing information for all GBCM
in the United States. However, prior reports of nephrotoxicity
in humans are likely related to very high off-label dosing of
GBCM (37,39), which is no longer applicable in the context
of current clinical care. There are no well-controlled clinical
studies demonstrating a clinically important nephrotoxic risk
at on-label doses of GBCM (40,41). Existing literature imply6

ing a potential risk of nephrotoxicity in humans are uncontrolled retrospective studies and case reports (42–44). Since
on-label dosing of intravenous GBCM is not associated with a
clinically relevant risk of AKI, no prophylaxis is indicated for
patients who will receive an on-label dose of group II or group
III GBCM.

Should Any of the Above Recommendations
Be Altered in Patients Receiving Nephrotoxic
Medications, Chemotherapy, or Contrastenhanced CT?
In general, the above recommendations should not be altered
in patients receiving nephrotoxic medications, chemotherapy,
or contrast-enhanced CT. Nephrotoxic drugs do not need to
be withheld prior to an on-label dose of group II or group III
GBCM. Contrast-enhanced MRI may be performed immediately before or after contrast-enhanced CT (and vice versa)
without additional safety concerns. Because of the weak x-ray
attenuating properties of GBCM, residual interstitial, urinary
tract, or vascular GBCM may mildly alter the appearance of
normal and pathologic structures at CT. However, for almost
all clinical indications, residual in vivo GBCM will not affect
the diagnostic value of CT.

How Much Time Should Elapse between
Sequential GBCM Administrations?
Similar to the risk in patients receiving a single standard dose
(0.1 mmol/kg) of group II or group III GBCM, the risk of
NSF from multiple, closely spaced, standard doses of group
II or group III GBCM in patients with eGFR greater than
or equal to 30 mL/min per 1.73 m2 is likely very small. The
risk of multiple closely spaced doses has not been evaluated
in patients with eGFR less than 30 mL/min per 1.73 m2.
If there is an urgent indication that requires closely spaced
doses, the examination(s) should not be delayed for fear of
NSF. If it is not medically inappropriate to delay a subsequent
examination, permitting greater than 24 hours to elapse or
an intercurrent dialysis session may allow greater clearance
of GBCM.

Should Any of the Above Be Altered in the
Pediatric Population?
In general, the aforementioned recommendations, including
those for the group III GBCM gadoxetate disodium, should not
be altered for infants and children. Kidney function measurement in infants and children should be evaluated by the Bedside
Schwartz equation or creatinine-cystatin C-based CKiD equation
rather than by eGFR equations that were developed and validated
in adults (45,46). NSF has been reported rarely in children (23
unique children aged 6 years or older from 1997–2012) (47). Of
the 17 children with NSF and reported exposure to GBCM, most
received only group I GBCM. None received a group III GBCM,
and there are no unconfounded cases in pediatric patients from a
group II GBCM (47). The risk of NSF in pediatric patients exposed to group II or group III GBCM is unknown. Interestingly,
there have been no reported cases of NSF in neonates or infants
radiology.rsna.org n Radiology: Volume 00: Number 0— 2020
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despite immature kidney function and eGFR measurements commonly less than 30 mL/min per 1.73 m2.

Summary
These joint consensus statements by the American College of
Radiology and the National Kidney Foundation are intended
to improve and standardize the care of patients with impaired
kidney function who have indication(s) to receive intravenous
gadolinium-based contrast media (GBCM). The risk of nephrogenic systemic fibrosis (NSF) or nephrotoxicity following
administration of a standard dose (0.1 mmol/kg) of a group II
GBCM is extremely low. The risk estimate of NSF for group II
GBCM in patients with stage 5 or 5D chronic kidney disease
is based on data from 2581 individuals. It is possible that NSF
may rarely occur in this population. The harms of delaying or
withholding group II GBCM for a clinically indicated MRI in
a patient with acute kidney injury or estimated glomerular filtration rate less than 30 mL/min per 1.73 m2 may outweigh the
risk of NSF, regardless of dialysis status. The safety margin of
group II GBCM should be considered with the potential harm
of delayed diagnosis or misdiagnosis. Further study investigating the clinical benefits of GBCM for common indications can
improve risk-benefit decision making. Kidney function screening prior to group II GBCM administration is optional. It is
not necessary to initiate or alter an established dialysis schedule
based on group II or group III GBCM administration. These
recommendations also apply to patients receiving nephrotoxic
medications, chemotherapy, or contrast-enhanced CT.
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